Clinical Trial Update: Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML [Phase 3]

View source ↗

Summary

This Phase 3 trial compares venetoclax plus decitabine with standard 7+3 induction chemotherapy in young adults with acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Decitabine (Decitabine)
• Venclexta (venetoclax)

Snippet

Sponsor: Chen Suning | Conditions: AML, Adult, Chemotherapy Effect | Phase 3 | Status: ACTIVE_NOT_RECRUITING